UNICYCIVE THERAPEUTICS INC (UNCY) Stock Earnings & Estimates
USA - NASDAQ:UNCY - US90466Y2028 - Common Stock
3.96 USD
0 (0%)
3.96 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 950K | 675K -28.95% | -100.00% | 5.312M | 243.35M 4,481.14% | 564.94M 132.15% | 578.33M 2.37% | 521.32M -9.86% | 539.62M 3.51% | 442.19M -18.06% | 341.61M -22.75% | ||
| EBITDA YoY % growth | -8.98M | -18.04M -100.89% | -20.49M -13.58% | N/A -54.66% | -42.432M -33.90% | 125.77M 396.40% | 577.42M 359.11% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.98M -344.55% | -18.05M -101.00% | -20.774M -15.09% | -30.664M -54.60% | -32.583M -1.45% | 145.31M 545.97% | 410.49M 182.49% | 398.24M -2.98% | 349.96M -12.12% | 360.37M 2.97% | 301.91M -16.22% | 207.02M -31.43% | |
| Operating Margin | N/A | -1,900.00% | -3,077.63% | N/A | -613.38% | 59.71% | 72.66% | 68.86% | 67.13% | 66.78% | 68.28% | 60.60% | |
| EPS YoY % growth | N/A | -12.00 -58.27% | -16.10 -34.17% | -5.14 33.54% | -2.59 75.77% | 6.28 342.01% | 18.98 202.42% | 16.27 -14.28% | 12.65 -22.26% | 9.86 -22.04% | 10.33 4.74% | 6.82 -33.95% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.63 -25.97% | -0.21 91.76% | 0.10 119.18% | 4.60 984.65% | 6.15 1,076.52% | 5.87 2,838.10% |
| Revenue Q2Q % growth | 1.216M | 31.072M | 82.843M | 122.69M | 154.03M 12,566.94% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.234M -31.72% | -8.663M 6.46% | 52.249M 655.41% | 94.765M 1,085.56% | 147.92M 1,896.44% | 210.53M 2,530.32% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.52 65.33% | -0.75 | 0.23 | 31.11% |
| Q1 2025 Q2Q % growth | -0.50 91.80% | -1.16 | 0.66 | 56.75% |
| Q4 2024 Q2Q % growth | -2.60 -18.18% | -0.92 | -1.68 | -183.22% |
| Q3 2024 Q2Q % growth | -0.50 61.54% | -1.55 | 1.05 | 67.68% |
| Q2 2024 Q2Q % growth | -1.50 48.28% | -1.96 | 0.46 | 23.27% |
| Q1 2024 Q2Q % growth | -6.10 37.11% | -1.58 | -4.52 | -285.83% |
| Q4 2023 Q2Q % growth | -2.20 37.14% | -1.71 | -0.49 | -28.77% |
| Q3 2023 Q2Q % growth | -1.30 64.86% | -1.22 | -0.08 | -6.21% |
| Q2 2023 Q2Q % growth | -2.90 -20.83% | -3.47 | 0.57 | 16.38% |
| Q1 2023 Q2Q % growth | -9.70 -304.17% | -3.80 | -5.90 | -155.30% |
| Q4 2022 Q2Q % growth | -3.50 -45.83% | -2.49 | -1.01 | -40.63% |
| Q3 2022 Q2Q % growth | -3.70 -362.50% | -2.86 | -0.84 | -29.55% |
| Q2 2022 Q2Q % growth | -2.40 -84.62% | -2.31 | -0.09 | -3.80% |
| Q1 2022 Q2Q % growth | -2.40 | -1.68 | -0.72 | -42.60% |
| Q4 2021 Q2Q % growth | -2.40 | -1.38 | -1.02 | -74.29% |
| Q3 2021 Q2Q % growth | -0.80 | -1.07 | 0.27 | 25.30% |
| Q2 2021 Q2Q % growth | -1.30 | -1.12 | -0.18 | -15.86% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | 675K | 382.5K | 292.5K | 76.47% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -71.72% | -1617.17% | 0% | -1066.06% |
| Revenue | N/A | N/A | -27.82% | -77.58% |